International: +1-(617)-969-5452 Toll Free: 800-370-5452
Stable, small uniform particle sizes with tight distributions is crucial for sterile filtration, increasing bioavailability and stability for pharmaceutical industry. The food and nutraceutical industries are also facing the challenge of achieving desired beverage clarity.
Let us use our collective 90 years of applications development and machine engineering experience to help drive your product to market as quickly as possible.
Microfluidics technology delivers not just highest shear forces, but also applies it uniformly to ensure that every mL of material undergoes the same high shear rates whether it is 1mL at a time up to many liters per minute to achieve nanoemulsions with tight distribution.
Microfluidizer® processors are designed to be simple to use and clean with the option of conforming to cGMP requirements.
Nanoemulsions with small particle sizes increase bioavailability and enable targeting (e.g., cancer drugs getting past the blood/brain barrier and inside cells). In manufacturing nanoemulsion vaccine adjuvants, we found that emulsions obtained from a Microfluidizer® processor were 18% – 55% smaller than the homogenized emulsions using the same energy input, while the standard deviations of the emulsions processed on a Microfluidizer® processor (0.1 – 2.6) were much lower than those of the homogenized emulsions (3.8 – 14.8)
Instability and phase separation of emulsions and suspensions are critical challenges faced by research and production teams, as most technologies cannot produce the particle size distribution necessary to reach product goals. To overcome these issues, Microfluidizer® processors use unique fixed-geometry interaction chambers to reduce particle sizes uniformly and to a level unmatched by other methods. This enables customers to optimize formulations for maximum stability, and to enjoy the cost efficiencies offered by products with a prolonged shelf life.
Compared to a homogenizer, the use of a Microfluidizer® processor usually allows customers to reduce the number of passes needed to reach particle size goals, and to simplify downstream processing steps as well, both of which have cost benefits.
Pharmaceutical applications, such as vaccine adjuvants, are often nanoemulsions requiring sterile filtration, and uniformly reducing particles to less than 200 nm significantly reduces the required filter area.
Biotechnology company CORIXA was able to reduce average particle size and tighten the distribution, to make sterile filtration possible.
Scaleup is guaranteed, bringing cost benefits to production volumes.
Enhancements such as translucent appearances for food or cosmetics products are more efficiently attainable with Microfluidics.